Archives

  • 2026-11
  • 2026-10
  • 2026-09
  • 2026-08
  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10
  • 2025-09
  • 2025-03
  • 2025-02
  • 2025-01
  • 2024-12
  • 2024-11
  • 2024-10
  • 2024-09
  • 2024-08
  • 2024-07
  • 2024-06
  • 2024-05
  • 2024-04
  • 2024-03
  • 2024-02
  • 2024-01
  • 2023-12
  • 2023-11
  • 2023-10
  • 2023-09
  • 2023-08
  • 2023-07
  • 2023-06
  • 2023-05
  • 2023-04
  • 2023-03
  • 2023-02
  • 2023-01
  • 2022-12
  • 2022-11
  • 2022-10
  • 2022-09
  • 2022-08
  • 2022-07
  • 2022-06
  • 2022-05
  • 2022-04
  • 2022-03
  • 2022-02
  • 2022-01
  • Preclinical Characterization of Anlotinib: Potent VEGFR2 Inh

    2026-07-19

    Preclinical Characterization of Anlotinib: Potent VEGFR2 Inhibition

    Study Background and Research Question

    Angiogenesis, the formation of new blood vessels from pre-existing vasculature, is a fundamental process in tumor progression, invasion, and metastasis. The vascular endothelial growth factor (VEGF) pathway, particularly the signaling through VEGFR2, is recognized as a central regulator of tumor angiogenesis. While monoclonal antibodies targeting VEGF/VEGFR2 have demonstrated clinical utility, small-molecule tyrosine kinase inhibitors (TKIs) often suffer from limited selectivity and attendant off-target effects. This has prompted a search for more selective, efficacious, and well-tolerated inhibitors suitable for anti-angiogenic therapy.

    The study by Xie et al. (Cancer Science, 2018) addresses the need for a potent and selective VEGFR2 inhibitor, evaluating the pharmacological and anti-angiogenic properties of anlotinib hydrochloride in preclinical models.

    Key Innovation from the Reference Study

    A distinguishing innovation in this work is the detailed demonstration of anlotinib’s exceptional selectivity and potency toward VEGFR2, with an IC50 of less than 1 nmol/L, markedly lower than for other kinases tested. Unlike earlier TKIs, which often target multiple kinases with limited specificity and thus introduce adverse events, anlotinib's molecular design enables it to occupy the ATP-binding pocket of VEGFR2 with high affinity. This results in robust inhibition of VEGF-induced signaling and downstream angiogenic processes at picomolar concentrations in endothelial cells. The study also highlights anlotinib’s oral bioavailability and tolerability, supporting its translational potential.

    Methods and Experimental Design Insights

    The authors employed a rigorous suite of in vitro and in vivo assays to characterize anlotinib’s pharmacological profile:
    • Biochemical kinase assays quantified anlotinib’s inhibitory activity against VEGFR2 and other receptor tyrosine kinases, confirming high selectivity and nanomolar efficacy.
    • Cellular assays using human umbilical vein endothelial cells (HUVECs) assessed inhibition of VEGF-induced proliferation, migration, and capillary-like tube formation, key hallmarks of angiogenesis.
    • Ex vivo rat aortic ring assays evaluated microvessel outgrowth in response to VEGF stimulation, providing a functional readout of anti-angiogenic activity in a complex tissue context.
    • In vivo efficacy was tested in tumor xenograft mouse models, where oral administration of anlotinib was compared to sunitinib, a well-established multi-target TKI.
    These complementary approaches allowed for a multi-layered assessment of both target engagement and functional outcomes relevant to tumor biology.

    Core Findings and Why They Matter

    The study’s findings underscore several critical points:
    • High Selectivity and Potency: Anlotinib exhibited sub-nanomolar inhibition of VEGFR2, with significantly reduced activity against other kinases. This specificity translated to potent inhibition of VEGF-driven endothelial cell proliferation and migration, with IC50 values in the picomolar range (reference).
    • Robust Anti-Angiogenic Activity: Functional assays demonstrated that anlotinib effectively suppresses endothelial cell migration and capillary tube formation—key steps in angiogenesis. In the rat aortic ring assay, anlotinib markedly reduced microvessel outgrowth, confirming its effect in a physiologically relevant ex vivo setting.
    • In Vivo Efficacy: In tumor xenograft models, once-daily oral dosing of anlotinib not only inhibited tumor growth but in some cases induced regression. Compared to sunitinib, anlotinib displayed broader and more potent antitumor effects, with reduced vascular density observed in treated tumor tissues.
    • Tolerability and Oral Bioavailability: The compound was well tolerated in animal studies, supporting its suitability for further clinical evaluation.
    These results collectively position anlotinib as a valuable tool for dissecting VEGFR2-driven angiogenic mechanisms and as a promising candidate for anti-angiogenic cancer therapy.

    Comparison with Existing Internal Articles

    Recent internal literature corroborates and expands upon these findings. For instance, the article "Preclinical Insights into Anlotinib’s Anti-Angiogenic Mechanisms" reinforces anlotinib’s high selectivity for VEGFR2 and its implications for optimizing angiogenesis inhibition assays. Similarly, "Anlotinib Hydrochloride: Multi-Target Tyrosine Kinase Inhibitor Insights" highlights its nanomolar efficacy for VEGFR2, PDGFRβ, and FGFR1, and its favorable safety profile for cancer research applications. Both sources stress the utility of anlotinib in reproducible endothelial cell migration inhibition and capillary tube formation assays, echoing the reference study’s methodology and conclusions.

    Limitations and Transferability

    While the preclinical data robustly support anlotinib’s anti-angiogenic effects and tolerability, several considerations remain. First, the high selectivity for VEGFR2, while desirable for minimizing off-target effects, may not account for the full complexity of angiogenic and tumor-promoting pathways in vivo, particularly in heterogeneous human tumors. Second, the majority of in vitro and animal efficacy data do not always translate directly to clinical outcomes, given pharmacokinetic and tumor microenvironmental differences. Finally, although the compound was well tolerated in preclinical models, long-term safety and efficacy in diverse patient populations require further clinical validation.

    Protocol Parameters

    • Kinase inhibition assays: Use sub-nanomolar to low nanomolar concentrations of anlotinib when assessing VEGFR2 inhibition; for PDGFRβ and FGFR1, IC50 values are typically in the 5–12 nM range, as reported in the reference study and product information.
    • Endothelial cell migration and tube formation: For HUVEC-based migration or capillary tube formation assays, researchers observed concentration-dependent inhibition at nanomolar doses; starting at 1 nM and titrating upward is recommended for maximal assay resolution.
    • In vivo dosing (preclinical): Oral administration in mouse xenograft models typically ranges from 1–10 mg/kg/day; efficacy and tolerability should be validated in pilot studies before scaling up.
    • Assay cytotoxicity controls: Anlotinib demonstrates minimal cytotoxicity up to 1 μM in functional endothelial assays, enabling clear interpretation of anti-angiogenic versus cytotoxic effects.
    Researchers should tailor concentrations and protocols to their specific cell lines and endpoints, referencing published dose-response data where possible.

    Research Support Resources

    For researchers aiming to replicate or extend these findings, high-purity anlotinib hydrochloride (SKU C8688) is available from APExBIO for experimental use in angiogenesis and cancer research workflows. Its documented selectivity, pharmacokinetics, and safety profile make it a reliable choice for functional assays exploring VEGFR2 signaling, endothelial migration, and capillary tube formation. For further context on practical applications, consult internal resources detailing workflow recommendations and comparative data.